Lab Owner Convicted in $18.7 Million COVID-Era Medicare Fraud Scheme

A federal jury in the District of Maryland convicted Patrick Britton-Harr, 42, of Annapolis, of five counts of health care fraud and one count of transactional money laundering for billing Medicare more than $18 million for respiratory tests that nursing home residents did not need, that physicians did not order, and that in many cases were never performed. Britton-Harr owned a laboratory in Arizona and operated through his company, Provista Health. He faces up to 10 years in prison on each count, with sentencing to be scheduled later.

According to evidence at trial, Britton-Harr offered COVID-19 tests to nursing homes across the country in 2020, when facilities were desperate for testing capacity. After specimens were collected and other laboratories ran the COVID-19 tests, he billed Medicare for separate, high-priced respiratory pathogen panel tests supposedly performed at his Arizona lab. The panels screened for more than 30 pathogens, and Britton-Harr falsely represented to Medicare that treating physicians had ordered them. Several physicians testified they had never ordered such a test in their careers. Prosecutors said he directed inexperienced staff, including a family member and high school and college interns, to bill for a panel every time a COVID-19 test was run. He also billed for tests supposedly performed after the lab had closed, and for residents who had already died.

Over roughly six months, Medicare was billed $18.7 million, and more than $7.2 million was paid. Trial evidence showed the proceeds funded a $112,500 Porsche 911 and $25,000 monthly mortgage payments on a waterfront home. Schemes built on unnecessary testing drain federal programs and can expose patients to needless procedures. Whistleblowers and qui tam actions under the False Claims Act often surface billing patterns that outside auditors miss, and reporting suspected fraud helps protect public health programs and taxpayer funds.